FDA Road To Decision On Expanding CBD Uses Starts With Weighing Impact On Existing And Future Use As Drug
Executive Summary
At public hearing, FDA officials starting with acting Commissioner Sharpless emphasized CBD is approved only as a drug and deciding on allowing its use in any other type of FDA-regulated product will be done with potential impact on drug development foremost in agency's thinking. Also apparent from questions 12-member panel of FDA officials asked was a potential regulatory pathway for clearing hemp and CBD as dietary ingredients will require resolving concerns about the substances' dose or concentration levels and establishing ingredient identity standards.
You may also be interested in...
In Second Term At Helm, Would Califf Steer US FDA On Supplement Market Regulation Changes?
CRN and NPA are receptive to former FDA Commissioner Robert Califf’s potential return to the post. NPA says his previous comments on FDA’s authority is a good sign he may help act on supplement industry issues stalled within the agency in recent years.
To Reach Sweet Spot In CBD Topical Permeation, Sweet Earth Relies On Nanotechnology
Sweet Earth conducts research with NAVCO Pharmaceuticals to confirm previous finding that beneficial effect of CBD is significantly impacted by skin permeation facilitated by nanotechnology. Canadian firm's CBD topicals are formulated with 70 nanometer particles.
Measuring Consumer Exposure Confounds US FDA’s Evaluation Of Cannabinoid Safety In Supplements
Acting commissioner Woodcock reminds manufacturers and marketers that a consumer’s exposure to cannabidiol and other cannabinoids likely comes from using multiple products daily. “How do you control exposure of people in a nonprescription setting?”